On Jul. 20, 2020, Sorrento announced that its partner Mabpharm had received approval of its New Drug Application for its infliximab biobetter antibody in China.

Infliximab (currently marketed under the trade name Remicade) is an injectable monoclonal antibody prescription drug used to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis (a type of spinal arthritis), psoriatic arthritis, and the red, scaly skin patches of plaque psoriasis.